Glenmark Generics Inc., the U.S. subsidiary of India-based Glenmark Generics Ltd., March 3 announced that the Food and Drug Administration has approved its generic version of UCB Inc.'s Xyzal (levocetirizine dihydrochloride) 5 milligram tablets.
Xyzal is indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis and the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria, according to UCB’s website.
Glenmark said its generic product currently is available and shipping will commence immediately.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.